8-K: LivaNova Q1 2026 Earnings: Revenue Up, Guidance Raised

LivaNova PLC reported strong first-quarter 2026 results, with revenue growth of 14.3% and raised full-year guidance for both revenue and adjusted diluted EPS.

Summary

• LivaNova PLC announced its first-quarter 2026 financial results, reporting total net revenue of $362.3 million, a 14.3% increase on a reported basis and 11.1% on a constant-currency basis compared to the prior year.
• The company raised its full-year 2026 revenue growth guidance to 7.0% to 8.0% on a constant-currency basis, up from 6.0% to 7.0%.
• Full-year 2026 adjusted diluted earnings per share (EPS) guidance was also increased to a range of $4.20 to $4.30, from $4.15 to $4.25.
• Net cash provided by operating activities was $15.2 million, and adjusted free cash flow was $3.8 million for the quarter.
• LivaNova received U.S. FDA premarket approval for its aura6000 System to treat obstructive sleep apnea (OSA).
• The company also announced positive 12-month results from the OSPREY trial for OSA, published in the Annals of Internal Medicine.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report due to strong revenue growth, raised full-year guidance, and a significant FDA approval, indicating solid operational performance and strategic progress.

Positives

• Double-digit reported and constant-currency revenue growth of 14.3% and 11.1% respectively in Q1 2026.
• Raised full-year 2026 revenue growth guidance by 100 basis points to 7.0% - 8.0% on a constant-currency basis.
• Increased full-year 2026 adjusted diluted EPS guidance by $0.05 at the midpoint to $4.20 - $4.30.
• Received U.S. FDA premarket approval for the aura6000 System for obstructive sleep apnea (OSA).
• Published positive 12-month results from the OSPREY randomized controlled trial for OSA.
• Cardiopulmonary revenue increased 18.3% reported and 14.0% constant-currency, driven by Essenz Perfusion System sales and consumables.
• Neuromodulation revenue increased 9.3% reported and 7.6% constant-currency, driven by implant growth and favorable pricing.

Negatives

• First-quarter 2026 U.S. GAAP diluted earnings per share was $0.40, a decrease from $0.40 in Q1 2025, though adjusted diluted EPS increased to $0.98 from $0.88.
• Net cash provided by operating activities decreased to $15.2 million in Q1 2026 from $24.0 million in Q1 2025.
• Adjusted free cash flow was $3.8 million in Q1 2026, down from $24.0 million in Q1 2025 (though the prior year's figure appears to be a typo in the filing, as the reconciliation shows $3.8M for Q1 2026 and $24.0M for Q1 2025 for net cash provided by operating activities, and adjusted free cash flow is not explicitly stated for Q1 2025 in the reconciliation table).
• The company's balance sheet shows a significant SNIA environmental liability of $389.5 million as of March 31, 2026.

Risks

• Volatility in the global market and worldwide economic conditions.
• Adverse changes in export/import costs, trade restrictions, and global tariffs.
• Supply chain pressures and potential disruptions.
• Failure to protect, maintain, or upgrade IT systems or products, or safeguard against cybersecurity incidents.
• Changes in technology and competition from superior or alternative technologies.
• Risks related to AI integration and regulation.
• Unfavorable results from clinical studies or failure to meet milestones.
• Product liability, intellectual property, environmental, and other litigation.

Future Outlook

LivaNova has raised its full-year 2026 revenue growth guidance to 7.0% to 8.0% on a constant-currency basis and its adjusted diluted EPS guidance to $4.20 to $4.30. The company maintained its full-year 2026 adjusted free cash flow guidance of $160 million to $180 million.

Management Comments

• "In the first quarter, LivaNova delivered double-digit revenue growth with strength across all regions, driven by sustained performance in our Cardiopulmonary and Epilepsy businesses," said Vladimir Makatsaria, Chief Executive Officer of LivaNova.
• "We also made meaningful progress in Obstructive Sleep Apnea, accomplishing key regulatory and clinical milestones. These achievements support a solid foundation for entry into the high-growth, high-margin OSA market with a differentiated technology."
• "Our updated 2026 guidance reflects strong execution in the core businesses alongside continued investment to unlock this next phase of growth and value creation."
• "We remain focused on disciplined execution as we advance our long-term strategy, consistent with what we outlined at our November 2025 Investor Day."

Industry Context

StockSavvy.ai notes that LivaNova's raised guidance and FDA approval for its OSA device position it favorably within the medical technology sector, particularly in the growing sleep apnea market. The company's performance in its core Cardiopulmonary and Neuromodulation segments also indicates resilience and execution against strategic objectives.

Comparison to Industry Standards

• The reported Q1 2026 revenue growth of 14.3% (11.1% constant-currency) for LivaNova exceeds the typical growth rates seen in many mature medical device segments, suggesting strong market penetration or demand for its specific products.
• The FDA approval for the aura6000 System without contraindications for complete concentric collapse is a significant differentiator in the hypoglossal nerve stimulation (HGNS) market, potentially setting a new standard compared to existing or emerging competitors.
• The company's focus on both core business growth and investment in new markets like OSA aligns with industry trends of diversification and innovation to drive long-term value.

Legal Proceedings

• The company mentions ongoing legal expenses related to 3T Heater-Cooler defense and litigation provision.
• MDR (Medical Device Regulation) costs are also noted as a factor.

Stakeholder Impact

• Shareholders: Positive impact expected from raised guidance and FDA approval, potentially leading to increased stock value.
• Employees: Continued focus on execution and strategy may lead to growth opportunities.
• Customers: Access to new medical technologies like the aura6000 System for OSA patients.
• Healthcare Systems: Introduction of innovative devices for treating neurological and cardiac conditions.

Next Steps

• Continue disciplined execution of long-term strategy.
• Advance entry into the high-growth OSA market with the aura6000 System.
• Host business update conference call and webcast to discuss financial results.

Key Dates

Recommendation

The company demonstrated robust Q1 performance with double-digit revenue growth, significantly raised its full-year guidance for both revenue and EPS, and achieved a critical FDA approval for a new product in a high-growth market. These factors collectively suggest strong execution and a positive trajectory, warranting a strong buy recommendation for investors.

Keywords

LivaNova, Medical Technology, Q1 2026 Earnings, Revenue Growth, Guidance Increase, Obstructive Sleep Apnea, FDA Approval, aura6000 System